Similar articles

• Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.

  Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Parikh CR, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ; Irbesartan Diabetic Nephropathy Trial. Collaborative Study Group. Berl T, et al. Ann Intern Med. 2003 Apr 1;138(7):542-9. doi: 10.7326/0003-4819-138-7-200304010-00010. Ann Intern Med. 2003. PMID: 12667024 Clinical Trial.
• Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

  Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group. Lewis EJ, et al. N Engl J Med. 2001 Sep 20;345(12):851-60. doi: 10.1056/NEJMoa011303. N Engl J Med. 2001. PMID: 11565517 Clinical Trial.
• The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.

  Rodby RA, Rohde RD, Clarke WR, Hunsicker LG, Anzalone DA, Atkins RC, Ritz E, Lewis EJ. Rodby RA, et al. Nephrol Dial Transplant. 2000 Apr;15(4):487-97. doi: 10.1093/ndt/15.4.487. Nephrol Dial Transplant. 2000. PMID: 10727543 Clinical Trial.
• Treatment of diabetic nephropathy with angiotensin II receptor antagonist.

  Lewis EJ, Lewis JB. Lewis EJ, et al. Clin Exp Nephrol. 2003 Mar;7(1):1-8. doi: 10.1007/s101570300000. Clin Exp Nephrol. 2003. PMID: 14586737 Review.
• [The effect of angiotensin-converting enzyme inhibitors on the progression of chronic renal failure].

  Bernadet-Monrozies P, Rostaing L, Kamar N, Durand D. Bernadet-Monrozies P, et al. Presse Med. 2002 Nov 9;31(36):1714-20. Presse Med. 2002. PMID: 12467154 Review. French.